Janus Henderson Group PLC Sells 283,711 Shares of Maze Therapeutics, Inc. $MAZE

Janus Henderson Group PLC cut its stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 9.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,858,876 shares of the company’s stock after selling 283,711 shares during the period. Janus Henderson Group PLC owned approximately 0.05% of Maze Therapeutics worth $85,280,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Maze Therapeutics during the first quarter worth $57,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics during the first quarter worth $145,000. Rhumbline Advisers acquired a new position in Maze Therapeutics in the 1st quarter valued at about $80,000. Geode Capital Management LLC grew its position in shares of Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares in the last quarter.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $26.92 on Friday. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -10.64 and a beta of 2.14. The firm has a 50 day moving average of $27.36 and a 200-day moving average of $34.05. Maze Therapeutics, Inc. has a 52 week low of $12.81 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. On average, equities analysts forecast that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Truist Financial lowered their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $66.00.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10. Following the transaction, the chief marketing officer owned 14,609 shares in the company, valued at approximately $436,809.10. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 141,470 shares of company stock worth $3,902,714. 5.30% of the stock is owned by corporate insiders.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.